STAB (Statera BioPharma) Current Accrued Expense: $6.31 Mil (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Statera BioPharma Current Accrued Expense?

Statera BioPharma STAB Current Accrued Expense is $6.31 Mil as of Sep. 2022.

Statera BioPharma's Current Accrued Expense for the quarter that ended in Sep. 2022 was $6.31 Mil.

Statera BioPharma's quarterly Current Accrued Expense increased from Mar. 2022 ($1.55 Mil) to Jun. 2022 ($3.61 Mil) and increased from Jun. 2022 ($3.61 Mil) to Sep. 2022 ($6.31 Mil).

Statera BioPharma's annual Current Accrued Expense increased from Dec. 2019 ($0.00 Mil) to Dec. 2020 ($1.55 Mil) and increased from Dec. 2020 ($1.55 Mil) to Dec. 2021 ($1.75 Mil).

Statera BioPharma Current Accrued Expense Related Terms

Statera BioPharma Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Current Accrued Expense Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Current Accrued Expense
0.00 1.55 1.75

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 2.74 1.75 1.55 3.61 6.31

Statera BioPharma Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $6.31 Mil mean?
Statera BioPharma (STAB) has a Current Accrued Expense of $6.31 Mil as of Sep. 2022. Current Accrued Expense records the total amount of accrued expenses. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's Current Accrued Expense too high?
Statera BioPharma's current Current Accrued Expense is $6.31 Mil.
How does Statera BioPharma's Current Accrued Expense compare to NRBO and PALI?
Statera BioPharma's Current Accrued Expense of $6.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current Current Accrued Expense is $6.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (STAB) has a current Current Accrued Expense of $6.31 Mil. The current Current Accrued Expense is $6.31 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Statera BioPharma (STAB), the current Current Accrued Expense is $6.31 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.